Tested Applications
| Positive IP detected in | Raji cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| WB | See 1 publications below |
Product Information
17230-1-AP targets TLR9 in WB, IP, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | TLR9 fusion protein Ag11071 Predict reactive species |
| Full Name | toll-like receptor 9 |
| Calculated Molecular Weight | 1032 aa, 116 kDa |
| Observed Molecular Weight | 120 kDa, 60 kDa |
| GenBank Accession Number | BC032713 |
| Gene Symbol | TLR9 |
| Gene ID (NCBI) | 54106 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q9NR96 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
TLR9, also known as CD289, is a member of the Toll-like receptor (TLR) family, which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents and mediate the production of cytokines necessary for the development of effective immunity. TLR9 is a nucleotide-sensing TLR that is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides (PMID:14716310). Upon CpG stimulation, it induces B-cell proliferation, activation, survival, and antibody production (PMID:23857366). TLR9 acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion, and the inflammatory response (PMID:11564765, 17932028).
Protocols
| Product Specific Protocols | |
|---|---|
| IP protocol for TLR9 antibody 17230-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
